Home/Pipeline/Signatera™ MRD (Adjuvant De-escalation)

Signatera™ MRD (Adjuvant De-escalation)

Early-stage Breast Cancer

Clinical Utility StudyActiveN/A

Key Facts

Indication

Early-stage Breast Cancer

Phase

Clinical Utility Study

Status

Active

Company

Natera

About Natera

Natera's mission is to transform the management of cancer, pregnancy, and organ transplantation through advanced cell-free DNA analysis. The company has achieved a dominant position in minimal residual disease (MRD) testing with its Signatera™ assay, supported by over 400 peer-reviewed publications and a database of over 350,000 de-identified patient records. Its strategy centers on expanding its technology platform through acquisitions like Foresight Diagnostics, commercializing new tests like Zenith™ for rare disease, and leveraging its massive real-world data to accelerate biopharma partnerships and clinical adoption.

View full company profile

Therapeutic Areas

Oncology Women's Health Organ Health Rare Disease

Other Early-stage Breast Cancer Drugs

Drug	Company	Phase	Status
MammaPrint/BluePrint Clinical Utility Expansion	Agendia	Commercial	Active
Real-World Evidence (FLEX Study)	Agendia	Observational Study	Active
OncoTect for Taxanes in Early-Stage Breast Cancer	Aida Oncology	Clinical Validation	Active
Pathlight MRD Test	SAGA Diagnostics	Commercial	Active
GammaPod Commercialization & Clinical Adoption	Xcision Medical Systems	Commercial	Active